Athena [Analyst]'s questions to Compass Pathways PLC (CMPS) leadership • Q3 2024
Question
Athena, on behalf of an unnamed analyst, inquired if the decision to delay the COMP 006 top-line data readout was influenced by recent FDA feedback or a meeting, and asked about any other potential changes to trial operations.
Answer
Kabir Nath (Executive) clarified that the delay was a proactive decision made by Compass Pathways out of an "abundance of caution" after observing the Lykos AdCom process. He emphasized the goal was to protect the integrity of the trial's blinding and that it was not a result of direct FDA interaction. He also noted the company continues to seek ways to accelerate the trial.